Quarterly report pursuant to Section 13 or 15(d)

Non-Controlling Interests (Schedule of Non-Controlling Interests in Consolidated Entities) (Details)

v3.21.2
Non-Controlling Interests (Schedule of Non-Controlling Interests in Consolidated Entities) (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended 12 Months Ended
Jun. 30, 2021
Jun. 30, 2020
Jun. 30, 2021
Jun. 30, 2020
Dec. 31, 2020
Noncontrolling Interest [Line Items]          
NCI equity share $ 178,120   $ 178,120   $ 153,120
Net loss attributable to non-controlling interests (20,856) $ (15,149) (38,100) $ (26,847) (56,459)
Non-controlling interests in consolidated entities 140,020   140,020   96,661
FBIO Acquisition Corp VIII [Member]          
Noncontrolling Interest [Line Items]          
NCI equity share (202)   (202)   (7)
Net loss attributable to non-controlling interests     (96)   (27)
Non-controlling interests in consolidated entities $ (298)   $ (298)   $ (34)
Non-controlling ownership 32.00%   32.00%   10.00%
Aevitas [Member]          
Noncontrolling Interest [Line Items]          
NCI equity share $ (4,022)   $ (4,022)   $ (2,370)
Net loss attributable to non-controlling interests     (567)   (823)
Non-controlling interests in consolidated entities $ (4,589)   $ (4,589)   $ (3,193)
Non-controlling ownership 46.60%   46.60%   39.00%
Avenue [Member]          
Noncontrolling Interest [Line Items]          
NCI equity share $ 2,004   $ 2,004   $ 5,800
Net loss attributable to non-controlling interests     (1,507)   (3,974)
Non-controlling interests in consolidated entities $ 497   $ 497   $ 1,826
Non-controlling ownership 77.40%   77.40%   77.40%
Baergic [Member]          
Noncontrolling Interest [Line Items]          
NCI equity share $ (1,916)   $ (1,916)   $ (1,662)
Net loss attributable to non-controlling interests     (20)   (97)
Non-controlling interests in consolidated entities $ (1,936)   $ (1,936)   $ (1,759)
Non-controlling ownership 39.50%   39.50%   39.50%
Cellvation [Member]          
Noncontrolling Interest [Line Items]          
NCI equity share $ (1,356)   $ (1,356)   $ (1,089)
Net loss attributable to non-controlling interests     (70)   (182)
Non-controlling interests in consolidated entities $ (1,426)   $ (1,426)   $ (1,271)
Non-controlling ownership 22.10%   22.10%   22.10%
Checkpoint [Member]          
Noncontrolling Interest [Line Items]          
NCI equity share $ 57,779   $ 57,779   $ 41,704
Net loss attributable to non-controlling interests     (11,643)   (13,265)
Non-controlling interests in consolidated entities $ 46,136   $ 46,136   $ 28,439
Non-controlling ownership 81.10%   81.10%   80.40%
Coronado SO [Member]          
Noncontrolling Interest [Line Items]          
NCI equity share $ (290)   $ (290)   $ (290)
Net loss attributable to non-controlling interests     0   0
Non-controlling interests in consolidated entities $ (290)   $ (290)   $ (290)
Non-controlling ownership 13.00%   13.00%   13.00%
Cyprium [Member]          
Noncontrolling Interest [Line Items]          
NCI equity share $ (1,157)   $ (1,157)   $ 567
Net loss attributable to non-controlling interests     (638)   (1,478)
Non-controlling interests in consolidated entities $ (1,795)   $ (1,795)   $ (911)
Non-controlling ownership 29.80%   29.80%   30.50%
Helocyte [Member]          
Noncontrolling Interest [Line Items]          
NCI equity share $ (5,305)   $ (5,305)   $ (4,986)
Net loss attributable to non-controlling interests     (47)   (259)
Non-controlling interests in consolidated entities $ (5,352)   $ (5,352)   $ (5,245)
Non-controlling ownership 18.30%   18.30%   18.80%
JMC [Member]          
Noncontrolling Interest [Line Items]          
NCI equity share $ 800   $ 800   $ 138
Net loss attributable to non-controlling interests     (1,182)   491
Non-controlling interests in consolidated entities $ (382)   $ (382)   $ 629
Non-controlling ownership 7.20%   7.20%   7.10%
Mustang [Member]          
Noncontrolling Interest [Line Items]          
NCI equity share $ 133,046   $ 133,046   $ 116,060
Net loss attributable to non-controlling interests     (22,066)   (36,429)
Non-controlling interests in consolidated entities $ 110,980   $ 110,980   $ 79,631
Non-controlling ownership 82.20%   82.20%   80.90%
Oncogenuity [Member]          
Noncontrolling Interest [Line Items]          
NCI equity share $ (540)   $ (540)   $ (82)
Net loss attributable to non-controlling interests     (264)   (376)
Non-controlling interests in consolidated entities $ (804)   $ (804)   $ (458)
Non-controlling ownership 24.90%   24.90%   25.30%
Tamid [Member]          
Noncontrolling Interest [Line Items]          
NCI equity share $ (721)   $ (721)   $ (663)
Net loss attributable to non-controlling interests     0   (40)
Non-controlling interests in consolidated entities $ (721)   $ (721)   $ (703)
Non-controlling ownership 22.80%   22.80%   22.80%